CD4+ T-Cell Recovery and Clinical Outcome in HIV-1-Infected Patients Exposed to Multiple Antiretroviral Regimens: Partial Control of Viremia Is Associated with Favorable Outcome

AIDS Patient Care and STDs

Volumn 18, Issue 4, 2004, Pages 189-198

  Brigido, L ^a,b   Rodrigues, R ^a   Casseb, J ^c   Custodio, R M ^a   Fonseca, L A M ^c   Sanchez, M ^c   Duarte, A J S ^c  

^a INSTITUTO ADOLFO LUTZ   (Brazil)

^b MS   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ARTICLE; BRAZIL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOREACTIVITY; INFECTION CONTROL; INFLAMMATION; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OBSERVATION; OUTCOMES RESEARCH; STATISTICAL ANALYSIS; STRUCTURAL GENE; VIREMIA; VIRUS GENE; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; BRAZIL; CD4 LYMPHOCYTE COUNT; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 2142657392     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729104323038865     Document Type: Article

References (31)

1. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV infected individuals following initiation of ARV therapy. JAMA 1998;279:450-454.
2. Palella FJJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advance human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998;13:853-860.
3. Casseb J, Pereira Junior LC, Silva GL, Medeiros LA. Decreasing mortality and morbidity in adult AIDS patients from 1995 to 1997 at the Institute of Infectious Diseases Emilio Ribas, São Paulo, Brazil. AIDS Patient Care STDs 1999;13:213-214.
4. Fonseca L, Reingold A, Casseb J, Brigido L, Duarte AJS. Aids incidence and survival in a hospital-based cohort of asymptomatic HIV seropositive patients in São Paulo, Brazil. Int J Epidemiol 1999;28:1156-1160.
5. Department of Health and Human Services. Guideline for the Use of Antiretroviral Agents in HIV-1 Infect Adults and Adolescents. www.aidsinfo.nih.gov/guidelines 2003.
6. World Health Organization. Scaling up ARV therapy in resource-limited settings: Guidelines for a public health approach. www.saathii.org/Training%20Mannuals/2002.
7. Ministério da Saúde, CN-DST/Aids, Brazil. Recommendations for Antiretroviral Therapy in HIV-infected Adults and Adolescents - 2002/2003. www.aids.gov.br/final/tratamento/consenso_english_2003.htm
8. Campos-Mello DLP, Neves I, Souza B, Morgado MG. Viral load and CD4+ lymphocytes in HIV-1 positive individuals followed in Rio de Janeiro. Rev Inst Med Trop São Paulo 1999;41:S52.
9. Dewton DM, Marao VL, Stellin R, et al. HIV Viral load among male and female patients derived from different sites of São Paulo. Rev Inst Trop S Paulo 1999;41:S28.
10. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS 1999;13:F35-F43.
11. Wit FW, Van Leeuwen R, Weverling GJ, et al. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999;179:790-798.
12. Grabar S, Pradier C, Corfec E, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 2000;14:141-149.
13. Shirasaka T, Yarchoan R, O'Brien MC, et al. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: An in vitro comparative study. Proc Natl Acad Sci USA 1993;90:562-566.
14. Deeks SG, Barbour J, Matin J, Swanson M, Grant RM. Sustained CD4 T cell response after virologic failure of protease inhibitor based regimens in HIV infected patients. J Infect Dis 2000;181:946-953.
15. Brigido L, Rodrigues R, Casseb J, et al. Impact of partial replication control of antiretroviral therapy (ART) on clinical and immunological outcome. XIII International AIDS Conference [Abstract TuPeB3268]. Durban, South Africa, July 2000.
16. Fessel WJ, Krowka JF, Sheppard HW, et al. Dissociation of immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;23:314-320.
17. Hejdeman B, Lenkei R, Leandersson AC, et al. Clinical and immunological benefits from HAART in spite of limited viral load reduction in HIV-1 infection. Aids Res Hum Retroviruses 2001;17:277-286.
18. D'Ettorre G, Forcima G, Andreotti M, et al. Discordant response to ARV: HIV isolation, genotypic mutations, T-cell proliferation and cytokine production. AIDS 2002;16:1877-1885.
19. + T cell gains in human immunodeficiency infected patients with sustained viral suppression during antiretroviral. J Infect Dis 2003;187:1534-1543.
20. Centers for Disease Control. 1993. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1-19.
21. Brigido LFM, Rodrigues R, Casseb J, et al. Impact of adherence to antiretroviral therapy (ART) in HIV-1-infected patients at a university public service in São Paulo City, Brazil. Aids Patient Care Stds 2001;15:587-593.
22. D'Aquila RT, Shapiro JM, Brun-Vezinet F, et al. Drug resistance mutation in HIV-1. Top HIV Med 2002;10:21-25.
23. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;5265:1167-1170.
24. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26.
25. Deeks S, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002;16:201-207.
26. Kousignian I, Abgrall S, Duval X, et al. Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003;34:50-57.
27. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after imitating triple-drug-therapy. JAMA 2001;286:2568-2577.
28. Cole SR, Hernán MA, Robins JM, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 2003;158:687-694.
29. Van Vaerenbergh K, Harrer T, Schmit JC, et al. Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients. AIDS Res Hum Retroviruses 2002;18:419-426.
30. Antinori A, Luizzi G, Cingolani A, et al. Drug resistance mutation of HIV-1 in patients exhibiting increasing CD4 cell counts despite virological failure of HAART. AIDS 2001;15:2325-2357.
31. Nijhuis M, Deeks S, Boucher C. Implications of antiretroviral resistance on fitness. Curr Opinion Infect Dis 2001;14:23-28.